A PYMNTS Company

US: Senators ask FTC to review Biosimilar patent settlements

By  |  July 4, 2018

United States Senators Chuck Grassley (R-Iowa) and Amy Klobuchar (D-Minn.) recently sent a letter to Federal Trade Commission (FTC) Chairman Joseph Simons urging the “FTC to examine global patent settlements relating to biosimilars to ensure they are not in violation of antitrust laws.”

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to the Senators, “biologics constitute a substantial and increasing portion of our nation’s healthcare costs” and “without biosimilar competition, US patients and payers will likely see additional price increases on biologics in the years to come.”

    The letter notes that “pay for delay” settlements have been estimated to cost consumers US$3.5 billion per year.

    The letter states that the FTC has filed lawsuits and worked with Congress to stop pay-for-delay settlements, and the Senators indicated that they “would like to continue those efforts to combat these agreements and explore their impact on the biologic market.”

    Full Content: Grassley Senate

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.